Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of millions” of renminbi in a Series B+ financing round. The investors included Suzhou Wuzhong Economic and Technological Innovation Investment Partnership Limited and Suzhou Wuzhong Jingkai Intelligent Manufacturing Investment Partnership Limited. The proceeds will be used to accelerate research and development, regulatory filing, and industrial implementation of its cardiovascular full-cycle products.
Pengyang Yiliao: Product Portfolio and Market Position
Pengyang Yiliao, which has an initial public offering (IPO) on its agenda, boasts a range of intelligent monitoring and AI diagnosis series products. The company is particularly known for its global exclusive patented product, the 18 lead dynamic ECG analysis system. This system, along with its 8 and 3 approved products in China and the European Union (EU) respectively, represents Pengyang Yiliao’s commitment to innovation and quality in cardiovascular diagnostics.
Strategic Use of Funds
The funds raised in the Series B+ round will be crucial for Pengyang Yiliao to further develop and expand its product line. This investment will support the company’s efforts to enhance its research and development capabilities, expedite regulatory approvals, and scale up industrial production. By doing so, Pengyang Yiliao aims to solidify its position in the cardiovascular technology market and bring advanced diagnostic solutions to healthcare providers and patients.-Fineline Info & Tech
